Docosahexaenoic Acid Plus Piracetam Versus Piracetam Alone for Treatment of Breath-Holding Spells in Children: A Randomized Clinical Trial.
- Resource Type
- Academic Journal
- Authors
- Salamah A; Lecturer Pediatric Neurology, Faculty of Medicine, Pediatrics Department, Kafr El-Sheik University, Kafr El-Sheik, Egypt.; Darwish AH; Associate Professor Pediatric Neurology, Faculty of Medicine, Pediatrics Department, Tanta University, Gharbia, Egypt. Electronic address: amira.darwish@med.tanta.edu.eg.
- Source
- Publisher: Elsevier Science Publishing Country of Publication: United States NLM ID: 8508183 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5150 (Electronic) Linking ISSN: 08878994 NLM ISO Abbreviation: Pediatr Neurol Subsets: MEDLINE
- Subject
- Language
- English
Background: Piracetam is the most widely used drug in breath-holding spells (BHS); however, its efficacy might not be satisfying to parents. This study aimed to compare the efficacy of docosahexaenoic acid (DHA) plus piracetam with piracetam alone in reducing the frequency and severity of BHS in infants and preschool children.
Methods: This randomized clinical trial included two groups diagnosed with BHS. Group I included 50 patients who received DHA plus piracetam. Group II (control group) included 50 children who were managed with piracetam plus a placebo. Children were re-evaluated at one, three, and six months after treatment. Occurrences of BHS and drug side effects were recorded. The primary outcome was to evaluate the effect of the combined treatment of piracetam and DHA on the frequency and severity of spells.
Results: BHS were reported in only 16% of children six months after treatment with piracetam and DHA compared with 50% of those treated with piracetam only (P value = 0.001).
Conclusion: DHA plus piracetam is more effective than piracetam alone in decreasing the frequency and severity of BHS in children.
Competing Interests: Declaration of competing interest No financial or nonfinancial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.
(Copyright © 2023 Elsevier Inc. All rights reserved.)